Background: Rearranged during transfection () gene fusions are detected in 10-20% of thyroid cancer patients. Recently, fusion-positive metastatic thyroid cancers have attracted much attention owing to the FDA approval of two highly selective anti-RET tyrosine kinase inhibitors, namely, selpercatinib, and pralsetinib.

Areas Covered: This review summarizes the available evidence on the biological and predictive role of gene fusions in thyroid carcinoma patients and the latest screening assays currently used to detect these genomic alterations in histological and cytological specimens.

Expert Opinion: Management of advanced thyroid carcinoma has significantly evolved over the last decade thanks to the approval of three multikinase inhibitors, i.e. sorafenib, lenvatinib, cabozantinib, and of two selective RET-tyrosine inhibitors, i.e. selpercatinib and pralsetinib. In this setting, the detection of RET-fusions in advanced thyroid cancer specimens through the use of next-generation sequencing has become a commonly used strategy in clinical practice to select the best treatment options.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17446651.2022.2060819DOI Listing

Publication Analysis

Top Keywords

thyroid cancer
12
metastatic thyroid
8
gene fusions
8
inhibitors selpercatinib
8
thyroid carcinoma
8
advanced thyroid
8
thyroid
6
predictive molecular
4
molecular pathology
4
pathology metastatic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!